Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients With Unresectable Locally Advanced or Metastatic Malignant Melanoma

NCT01654692 is registered in ClinicalTrials.gov with Italian Network for Tumor Biotherapy as lead sponsor.

NCT NCT01654692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01654692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients With Unresectable Locally Advanced or Metastatic Malignant Melanoma
Lead sponsor
Italian Network for Tumor Biotherapy
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
September 30, 2014
Enrollment
86 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant melanoma